首页> 外文期刊>Cornea >Conjunctival impression cytology, ocular surface, and tear-film changes in patients treated with systemic isotretinoin.
【24h】

Conjunctival impression cytology, ocular surface, and tear-film changes in patients treated with systemic isotretinoin.

机译:全身异维A酸治疗的患者结膜印象细胞学,眼表和泪膜变化。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

PURPOSE: To evaluate the ocular surface changes and tear-film functions in patients treated with systemic isotretinoin. METHODS: Fifty subjects treated with 0.8 mg/kg oral isotretinoin were enrolled in this prospective clinical trial. All patients underwent a full ophthalmoscopic examination before, during, and after treatment with isotretinoin. Ocular surface changes of the cell content of the surface conjunctival epithelium were evaluated by conjunctival impression cytology and tear-film functions using the Schirmer test, anesthetized Schirmer test, tear breakup time, and rose bengal staining. Subjective ocular complaints were scored with an Ocular Surface Disease Index questionnaire. RESULTS: There were no significant differences observed in average Schirmer test scores for patients before, during, or after isotretinoin treatment. Mean anesthetized Schirmer test scores and tear breakup time decreased significantly during treatment (P < 0.001). Mean impression cytology scores, Ocular Surface Disease Index scores, and rose bengal staining scores increased significantly during treatment (P < 0.05, P < 0.001 and P < 0.001, respectively). Blepharitis was seen in 36% of patients. All abnormal findings disappeared 1 month after the cessation of treatment. CONCLUSIONS: Conjunctival epithelial cells, tear basal secretion, and tear quality are markedly affected in patients during systemic treatment with isotretinoin (0.8 mg/kg). Ocular adverse effects of isotretinoin are generally not serious and are reversible after discontinuation.
机译:目的:评估接受全身异维A酸治疗的患者的眼表变化和泪膜功能。方法:五十名接受0.8 mg / kg口服异维A酸治疗的受试者参加了这项前瞻性临床试验。所有患者在接受异维A酸治疗之前,期间和之后均接受全面的检眼镜检查。使用Schirmer试验,麻醉的Schirmer试验,泪液破裂时间和玫瑰红染色,通过结膜印模细胞学和泪膜功能评估结膜上皮细胞含量的眼表变化。用眼表疾病指数问卷对主观眼部不适进行评分。结果:异维A酸治疗之前,期间或之后,患者的平均Schirmer测试得分均无显着差异。在治疗期间,平均麻醉后的Schirmer测试评分和泪液破裂时间明显减少(P <0.001)。治疗期间平均印象细胞学评分,眼表疾病指数评分和孟加拉玫瑰染色评分显着增加(分别为P <0.05,P <0.001和P <0.001)。 36%的患者可见睑缘炎。停止治疗后1个月所有异常发现均消失。结论:异维A酸(0.8 mg / kg)全身治疗期间,结膜上皮细胞,泪液基础分泌物和泪液质量受到明显影响。异维A酸的眼部不良反应一般不严重,停药后可逆。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号